Skip to content

Beneficient BENF Payments Of Stock Issuance Costs

Payments Of Stock Issuance Costs at other companies

IRA
Iris Acquisition IRAB
$10.61M
EyePoint, Inc.
 logo
EyePoint, Inc. EYPT
$297K+119%
EPM
Evolution PetroleumEPM
$78K+11.4%
TRV
Trevi Therapeutics, Inc.TRVI
$0
Relmada Therapeutics, Inc. logo
Relmada Therapeutics, Inc.RLMD
$65.65K+260%
New Horizon Aircraft logo
New Horizon AircraftHOVR
$510K

Other financials

Income statement

See full
Revenue$18.7M+322%
Operating income$3.9M+141%
Net income$19.9M+331%
EPS (diluted)-$0.49+26.5%

Balance sheet

See full
Cash & equivalents$7.9M+87.3%
Total debt$100.3M-16.6%
Total equity-$128.6M-1,002%
Total assets$337.9M-15.5%

Cash flow

See full
Operating cash flow-$9.4M+6.3%
CapEx$96.0K-85.5%
Free cash flow-$9.4M+6.7%

Valuation

See full
Market cap$52.86M+2,018%
Enterprise value$145.33M+40.6%

Profitability

See full
Operating margin548.5%-323pp
Net margin517.9%-235pp
FCF margin156.8%-40.4pp

Returns & leverage

See full
Return on equity-1,647.1%-2,080pp
Debt / equity8.4×-23.8×

Where this comes from

Reported directly by Beneficient in its filing.

Tagged under the XBRL concept us-gaap:PaymentsOfStockIssuanceCosts.

The official record: Beneficient’s 10-Q, filed February 17, 2026, on SEC EDGAR. View the filing →

Ask your AI about Beneficient's payments of stock issuance costs.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Beneficient's payments of stock issuance costs?
Beneficient (BENF) reported payments of stock issuance costs of $0 in Q4 2025.
How has Beneficient's payments of stock issuance costs changed year-over-year?
Beneficient's payments of stock issuance costs decreased by 100.0% year-over-year, from $576K to $0.
What does payments of stock issuance costs mean?
Represents the cash outflows related to the issuance of equity securities, including legal, accounting, and registration fees. These costs reduce the net proceeds received from equity offerings. Tracking these expenses provides insight into the cost-efficiency of the company's equity financing strategy.